text_1: Tonic signaling from the scFv is amplified by MyD88/CD40.
text_2: Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens.